|
|
Actimmune - Newsfeeds
-
-
The INSPIRE trial, being conducted in 70 centers in North America, Europe, and Canada, is testing the safety and efficacy of Actimmune (interferon gamma-1b), a disease-modifying drug with a low side effect profile. Interferon gamma-1b is a cytokine ...
-
-
You should not receive this medicine if you have had an allergic reaction to interferon alfa-2a or to benzyl alcohol, or if you have ever had autoimmune hepatitis or other severe liver problems, or if you have a weakened immune system. This medicine should ...
-
-
Rarely, systemic agents (e.g., cyclosporine, interferon gamma-1b, oral corticosteroids) may be considered in adults. Evaluation and Treatment of Acute Low Back Pain - Article ABSTRACT: Acute low back pain with or without sciatica usually is self-limited ...
-
-
NEW YORK - Wednesday, InterMune announced results for its lead drug, Actimmune, that even the company admitted were not necessarily good enough to get the drug past U.S. regulators for the indication being studied. Still, shares jumped nearly 26% to $22.66.
-
-
Revenue for 2009, including Actimmune(R) and anticipated milestone payments from Roche, is expected to be in a range of approximately $40 to $50 million . Actimmune revenue represents approximately 50% of this revenue range. R&D expense is anticipated to ...
-
-
Under Harkonen’s direction, the Justice Department alleged, InterMune marketed and sold its $50,000-per-year Actimmune IPF treatment despite not receiving Food and Drug Administration approval. He did so, authorities said, to boost InterMune’s revenue and profit.
-
-
o InterMune Inc., of Brisbane, Calif., completed enrollment in itspivotal Phase III trial evaluating the safety and efficacy of Actimmune (interferon gamma-1b) in combination with standard chemotherapy for advanced ovarian cancer. Initiated in 2001, the ...
-
-
(See BioWorld Today, May 3, 2001.) It also received $92,000 in royalties from InterMune Inc. for Actimmune sales in the U.S. Actimmune is approved to treat chronic granulomatous disease and severe, malignant osteopetrosis. Connetics acquired the product ...
-
-
Investigators in the Hotchkiss Brain Institute, Faculty of Medicine, have made a major breakthrough in our understanding of nerve impulse generation within the brain . Brain cells communicate with each other by firing electrical impulses, which in turn ...
-
-
The company primarily offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease. Its pulmonology product portfolio includes lead product candidate, pirfenidone, a phase III product being ...
-
-
Raleigh | California drugmaker InterMune Inc. has paid nearly $570,000 to North Carolina as part of a $36.9 million national settlement to resolve allegations that it unlawfully marketed its drug Actimmune for unapproved uses, N.C. Attorney Gen.
-
-
The company primarily offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease. Its pulmonology product portfolio includes lead product candidate, pirfenidone, a phase III product being ...
-
-
The company primarily offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease. Its pulmonology product portfolio includes lead product candidate, pirfenidone, a phase III product being ...
-
-
The plaintiffs argued the companies illegally marketed the drug Actimmune for patients suffering from idiopathic pulmonary fibrosis, a lung disease without a known cure, even though it was not approved by the Food ...
-
-
Law360, New York (November 10, 2009) -- A federal judge has dismissed fraud claims from a suit brought by a putative class of patients and Zurich Insurance Co. alleging that biotechnology company InterMune Inc. fraudulently promoted its drug ...
-
-
Total revenue in the first quarter of 2009 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $6.0 million, compared with $8.5 million in the same quarter of 2008, a decrease of approximately 29%, reflecting lower off-label ...
-
-
Total revenue in the second quarter of 2009 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $7.1 million, compared with $7.3 million in the same quarter of 2008, a decrease of approximately 2 percent, reflecting lower off-label ...
-
-
"We cannot recommend treatment with interferon gamma-1b since the drug did not improve survival for patients with idiopathic pulmonary fibrosis, which refutes previous findings from subgroup analyses of survival in studies of patients with mild-to ...
-
-
Many launches tied in with the show’s green theme, such as Beraca’s new ARS active revitalization hair system and its Buriti extract, PL Thomas’s Lipowheat nutricosmetic ingredient, and Active Organics’s Actilipid, Actifirm Age and ActImmune ...
-
-
Federal prosecutors accuse him of illegally marketing the company's drug Actimmune; the case will likely be the first of its kind to reach a jury. Arch Specialty Insurance Co.'s decision -- which, coming before a conviction, is rare -- prompted a pair ...
Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.
Pages:
1
2
Next
|
|
